368 related articles for article (PubMed ID: 35848888)
21. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic modulation of antitumor immunity and immunotherapy response in breast cancer: biological mechanisms and clinical implications.
Yin J; Gu T; Chaudhry N; Davidson NE; Huang Y
Front Immunol; 2023; 14():1325615. PubMed ID: 38268926
[TBL] [Abstract][Full Text] [Related]
23. Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors.
Hou A; Hou K; Huang Q; Lei Y; Chen W
Front Immunol; 2020; 11():783. PubMed ID: 32508809
[TBL] [Abstract][Full Text] [Related]
24. Treg-mediated acquired resistance to immune checkpoint inhibitors.
Saleh R; Elkord E
Cancer Lett; 2019 Aug; 457():168-179. PubMed ID: 31078738
[TBL] [Abstract][Full Text] [Related]
25. Immunometabolism: a new dimension in immunotherapy resistance.
Xiao C; Xiong W; Xu Y; Zou J; Zeng Y; Liu J; Peng Y; Hu C; Wu F
Front Med; 2023 Aug; 17(4):585-616. PubMed ID: 37725232
[TBL] [Abstract][Full Text] [Related]
26. Targeting immune checkpoints in hematological malignancies.
Salik B; Smyth MJ; Nakamura K
J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks.
Meng L; Wu H; Wu J; Ding P; He J; Sang M; Liu L
Cell Death Dis; 2024 Jan; 15(1):3. PubMed ID: 38177102
[TBL] [Abstract][Full Text] [Related]
28. Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors.
Ouyang P; Wang L; Wu J; Tian Y; Chen C; Li D; Yao Z; Chen R; Xiang G; Gong J; Bao Z
Front Immunol; 2024; 15():1344272. PubMed ID: 38545114
[TBL] [Abstract][Full Text] [Related]
29. Overcoming Resistance Mechanisms to Immune Checkpoint Inhibitors: Leveraging the Anti-Tumor Immune Response.
Coschi CH; Juergens RA
Curr Oncol; 2023 Dec; 31(1):1-23. PubMed ID: 38275827
[TBL] [Abstract][Full Text] [Related]
30. Targeting the antigen processing and presentation pathway to overcome resistance to immune checkpoint therapy.
D'Amico S; Tempora P; Melaiu O; Lucarini V; Cifaldi L; Locatelli F; Fruci D
Front Immunol; 2022; 13():948297. PubMed ID: 35936007
[TBL] [Abstract][Full Text] [Related]
31. New developments in the mechanism and application of immune checkpoint inhibitors in cancer therapy (Review).
Wang Y; Yang S; Wan L; Ling W; Chen H; Wang J
Int J Oncol; 2023 Jul; 63(1):. PubMed ID: 37326100
[TBL] [Abstract][Full Text] [Related]
32. CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy.
Lai AY; Sorrentino JA; Dragnev KH; Weiss JM; Owonikoko TK; Rytlewski JA; Hood J; Yang Z; Malik RK; Strum JC; Roberts PJ
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33004541
[TBL] [Abstract][Full Text] [Related]
33. Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer.
Kobayashi Y; Lim SO; Yamaguchi H
Semin Cancer Biol; 2020 Oct; 65():51-64. PubMed ID: 31874279
[TBL] [Abstract][Full Text] [Related]
34. Radiotherapy-induced tumor physical microenvironment remodeling to overcome immunotherapy resistance.
Peng J; Yin X; Yun W; Meng X; Huang Z
Cancer Lett; 2023 Apr; 559():216108. PubMed ID: 36863506
[TBL] [Abstract][Full Text] [Related]
35. Resistance to systemic immune checkpoint inhibition in the peritoneal niche.
Chia DKA; Gwee YX; Sundar R
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35728873
[TBL] [Abstract][Full Text] [Related]
36. Tissue biomarkers of immune checkpoint inhibitor therapy.
Davoudi F; Moradi A; Sadeghirad H; Kulasinghe A
Immunol Cell Biol; 2024 Mar; 102(3):179-193. PubMed ID: 38228572
[TBL] [Abstract][Full Text] [Related]
37. Is there a role for Gallium-67 SPECT in distinguishing progression and pseudoprogresion in oncologic patients receiving immunotherapy?
Mauri D; Tsiouris S; Gkoura S; Gazouli I; Ntellas P; Amylidis A; Kampletsas L; Fotopoulos A
Cancer Treat Res Commun; 2021; 28():100441. PubMed ID: 34404012
[TBL] [Abstract][Full Text] [Related]
38. Resistance to Immune Checkpoint Blockade: IFNγ or MHC-I?
Haugh A; Daud A
Cancer Immunol Res; 2023 Jul; 11(7):864. PubMed ID: 37262325
[TBL] [Abstract][Full Text] [Related]
39. Acquired resistance for immune checkpoint inhibitors in cancer immunotherapy: challenges and prospects.
Chen X; Zhang W; Yang W; Zhou M; Liu F
Aging (Albany NY); 2022 Jan; 14(2):1048-1064. PubMed ID: 35037899
[TBL] [Abstract][Full Text] [Related]
40. The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors.
Tosi A; Parisatto B; Menegaldo A; Spinato G; Guido M; Del Mistro A; Bussani R; Zanconati F; Tofanelli M; Tirelli G; Boscolo-Rizzo P; Rosato A
J Exp Clin Cancer Res; 2022 Sep; 41(1):279. PubMed ID: 36123711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
